Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
about
Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cisplatin induces tolerogenic ...... nd Tr1-biased T-cell immunity.
@en
Cisplatin induces tolerogenic ...... nd Tr1-biased T-cell immunity.
@nl
type
label
Cisplatin induces tolerogenic ...... nd Tr1-biased T-cell immunity.
@en
Cisplatin induces tolerogenic ...... nd Tr1-biased T-cell immunity.
@nl
prefLabel
Cisplatin induces tolerogenic ...... nd Tr1-biased T-cell immunity.
@en
Cisplatin induces tolerogenic ...... nd Tr1-biased T-cell immunity.
@nl
P2093
P2860
P50
P356
P1433
P1476
Cisplatin induces tolerogenic ...... and Tr1-biased T-cell immunity
@en
P2093
Bo Ryeong Lee
Hongmin Kim
Kee Woong Kwon
Woo Sik Kim
P2860
P304
33765-33782
P356
10.18632/ONCOTARGET.9260
P407
P577
2016-06-01T00:00:00Z